zonisamide has been researched along with Convulsive Generalized Seizure Disorder in 22 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 9.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| "Zonisamide treatment was generally well tolerated and was associated with significant reductions in seizure frequency in this pediatric population with a variety of both partial and generalized medically refractory epilepsy syndromes." | 5.14 | Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy. ( Conry, JA; Pellock, JM; Shinnar, S, 2009) |
| " Antiepileptics (carbamazepine, sodium valproate, zonisamide, clobazam, and topiramate), which are used for complex partial epilepsy or secondary generalized epilepsy in clinical practice, were orally administrated to kindled rats." | 3.76 | The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics. ( Akagi, M; Fujiwara, A; Ishikawa, T; Kaida, Y; Kamei, C; Takechi, K; Watanabe, Y, 2010) |
| " The guidelines for clinical evaluation of antiepileptic drugs (AEDs), proposed by the International League Against Epilepsy in 1989, were scrutinized through our clinical experiences with zonisamide." | 3.68 | Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide. ( Seino, M; Yagi, K, 1992) |
| "Fifteen drug-naïve idiopathic generalized epilepsy (IGE) patients (8 male, mean age 24." | 2.73 | Zonisamide decreases cortical excitability in patients with idiopathic generalized epilepsy. ( Hong, SB; Joo, EY; Kim, SH; Seo, DW, 2008) |
| "It is also effective in generalized epilepsy and in several other conditions of the CNS." | 2.61 | An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy. ( Ljung, H; Reimers, A, 2019) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Epilepsy is a common neurological condition with a worldwide prevalence of around 1%." | 2.55 | Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. ( Marson, AG; Nevitt, SJ; Sudell, M; Tudur Smith, C; Weston, J, 2017) |
| "Juvenile myoclonic epilepsy is a common idiopathic generalized epileptic syndrome that includes generalized myoclonic seizures and commonly generalized tonic-clonic and generalized absence seizures." | 2.45 | The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent? ( Abou-Khalil, B; Montouris, G, 2009) |
| "Under lamotrigine, seizure aggravation was observed in 15 patients (two patients during levetiracetam, one patient during zonisamide, none during phenobarbital and valproic acid)." | 1.62 | Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy. ( Beier, CP; Gesche, J; Hjalgrim, H; Rubboli, G, 2021) |
| "Zonisamide was the first-line and second-line monotherapy for 32% and 68% of patients, respectively." | 1.33 | Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy. ( Hobdell, E; Kaleyias, J; Khurana, DS; Kothare, SV; Legido, A; Melvin, JJ; Mostofi, N; Valencia, I, 2006) |
| "The recommended treatment for juvenile myoclonic epilepsy (JME) is valproate (VPA)." | 1.32 | Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy. ( Hardison, H; Khurana, DS; Kothare, SV; Legido, A; Melvin, JJ; Valencia, I, 2004) |
| "Zonisamide was changed to sodium valproate." | 1.31 | Smoldering myeloma associated with zonisamide treatment. ( Ando, Y; Asai, S; Hotta, T; Kobayashi, H; Miyachi, H, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.55) | 18.2507 |
| 2000's | 14 (63.64) | 29.6817 |
| 2010's | 6 (27.27) | 24.3611 |
| 2020's | 1 (4.55) | 2.80 |
| Authors | Studies |
|---|---|
| Gesche, J | 1 |
| Hjalgrim, H | 1 |
| Rubboli, G | 1 |
| Beier, CP | 1 |
| Coppola, G | 1 |
| Piccorossi, A | 1 |
| Operto, FF | 1 |
| Verrotti, A | 1 |
| Nevitt, SJ | 2 |
| Sudell, M | 2 |
| Weston, J | 2 |
| Tudur Smith, C | 2 |
| Marson, AG | 2 |
| Reimers, A | 1 |
| Ljung, H | 1 |
| Zachry, WM | 1 |
| Doan, QD | 1 |
| Clewell, JD | 1 |
| Smith, BJ | 1 |
| Marinas, A | 1 |
| Villanueva, V | 1 |
| Giráldez, BG | 1 |
| Molins, A | 1 |
| Salas-Puig, J | 1 |
| Serratosa, JM | 1 |
| Montouris, G | 1 |
| Abou-Khalil, B | 4 |
| Fujiwara, A | 1 |
| Watanabe, Y | 1 |
| Takechi, K | 1 |
| Ishikawa, T | 1 |
| Kaida, Y | 1 |
| Akagi, M | 1 |
| Kamei, C | 1 |
| Kelemen, A | 1 |
| Rásonyl, G | 1 |
| Neuwirth, M | 1 |
| Barcs, G | 1 |
| Szucs, A | 1 |
| Jakus, R | 1 |
| Fabó, D | 1 |
| Juhos, V | 1 |
| Pálfy, B | 1 |
| Halász, P | 1 |
| French, JA | 3 |
| Kanner, AM | 3 |
| Bautista, J | 3 |
| Browne, T | 3 |
| Harden, CL | 3 |
| Theodore, WH | 3 |
| Bazil, C | 3 |
| Stern, J | 3 |
| Schachter, SC | 3 |
| Bergen, D | 3 |
| Hirtz, D | 3 |
| Montouris, GD | 3 |
| Nespeca, M | 3 |
| Gidal, B | 3 |
| Marks, WJ | 3 |
| Turk, WR | 3 |
| Fischer, JH | 3 |
| Bourgeois, B | 3 |
| Wilner, A | 3 |
| Faught, RE | 3 |
| Sachdeo, RC | 3 |
| Beydoun, A | 3 |
| Glauser, TA | 3 |
| Kothare, SV | 2 |
| Valencia, I | 2 |
| Khurana, DS | 2 |
| Hardison, H | 1 |
| Melvin, JJ | 2 |
| Legido, A | 2 |
| Mandelbaum, DE | 2 |
| Bunch, M | 2 |
| Kugler, SL | 2 |
| Venkatasubramanian, A | 2 |
| Wollack, JB | 2 |
| Kaleyias, J | 1 |
| Mostofi, N | 1 |
| Hobdell, E | 1 |
| Shinnar, S | 1 |
| Pellock, JM | 1 |
| Conry, JA | 1 |
| Joo, EY | 1 |
| Kim, SH | 1 |
| Seo, DW | 1 |
| Hong, SB | 1 |
| Asai, S | 1 |
| Miyachi, H | 1 |
| Kobayashi, H | 1 |
| Hotta, T | 1 |
| Ando, Y | 1 |
| Yagi, K | 1 |
| Seino, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Characterization of Epilepsy Patients At-risk for Adverse Outcomes Related to Switching Antiepileptic Drug Products: BEEP 2b Study[NCT02707965] | Phase 1 | 21 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs[NCT02429596] | Phase 4 | 200 participants (Anticipated) | Interventional | 2012-05-31 | Recruiting | ||
| Phase 3: Metabolism of Lamotrigine During Treatment With Oral Contraceptives[NCT00266149] | Phase 3 | 10 participants | Interventional | 2003-06-30 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
summed for each anti-epileptic drug from when taking brand and generic. (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | events (Number) |
|---|---|
| Topiramate | 29 |
| Lamotrigine ER | 9 |
| Levetiracetam IR | 17 |
| Levetiracetam ER | 4 |
| Carbamazepine ER Capsule | 15 |
| Zonisamide | 6 |
| Carbamazepine ER Tablet | 10 |
| Valproic Acid | 10 |
Average AUC (area under the drug plasma curve. (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | micro/mL/hr (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 114.96 | 106.45 |
| Carbamazepine ER Tablet | 104.6 | 115.16 |
| Lamotrigine ER Tablet | 62.76666667 | 67.19333333 |
| Levetiracetam ER Tablet | 260.3 | 262.305 |
| Levetiracetam IR Tablet | 419.97 | 445.2 |
| Topiramate Tablet | 92.884 | 94.456 |
| Zonisamide Capsule | 233.16 | 226.14 |
Average maximum drug plasma concentration; (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 10.95 | 9.91 |
| Carbamazepine ER Tablet | 10.00 | 10.6 |
| Lamotrigine ER Tablet | 6.24 | 6.903333333 |
| Levetiracetam ER Tablet | 31.05 | 28.04 |
| Levetiracetam IR Tablet | 71.02333333 | 69.29333333 |
| Topiramate Tablet | 9.874 | 9.646 |
| Zonisamide Capsule | 12.29 | 11.68 |
Average minimum drug plasma concentration (Cmin); (NCT02707965)
Timeframe: For all study drugs, time points are: predose, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, and 6 hr postdose. For twice-a-day regimen, additional points are:8, 10, and 12 hr postdose. For once-a-day drugs, additional times are:8, 10, 12, 16, and 24 hr postdose.
| Intervention | microg/mL (Mean) | |
|---|---|---|
| Test Product | Reference Product | |
| Carbamazepine ER Capsule | 8.56 | 7.66 |
| Carbamazepine ER Tablet | 7.37 | 7.97 |
| Lamotrigine ER Tablet | 4.053333333 | 4.21 |
| Levetiracetam ER Tablet | 12.605 | 14.395 |
| Levetiracetam IR Tablet | 15.45333333 | 17.45666667 |
| Topiramate Tablet | 6.326 | 6.53 |
| Zonisamide Capsule | 8.46 | 8.34 |
Number of seizures reported in all groups (NCT02707965)
Timeframe: Through the approximately 2 week period when the treatment is given.
| Intervention | Number of Seizures (Number) | |
|---|---|---|
| Reference Product | Test (Generic) | |
| Carbamazepine ER Capsule | 3 | 1 |
| Carbamazepine ER Tablet | 0 | 0 |
| Lamotrigine ER Tablet Group | 44 | 25 |
| Lamotrigine IR Tablet Group | 0 | 0 |
| Levetiracetam ER Tablet Group | 42 | 72 |
| Levetiracetam IR Tablet Group | 16 | 5 |
| Topiramate Tablet Group | 9 | 5 |
| Valproic Acid ER Tablet Group | 12 | 0 |
| Zonisamide Capsule Group | 0 | 0 |
8 reviews available for zonisamide and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Anticonvulsant drugs for generalized tonic-clonic epilepsy.
Topics: Acetamides; Anticonvulsants; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Female; Fructose; Humans | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.
Topics: Adult; Amines; Anticonvulsants; Carbamazepine; Child; Cyclohexanecarboxylic Acids; Epilepsies, Parti | 2017 |
An evaluation of zonisamide, including its long-term efficacy, for the treatment of focal epilepsy.
Topics: Adult; Anticonvulsants; Carbamazepine; Child; Epilepsies, Partial; Epilepsy, Generalized; Humans; Se | 2019 |
The first line of therapy in a girl with juvenile myoclonic epilepsy: should it be valproate or a new agent?
Topics: Anticonvulsants; Congenital Abnormalities; Delayed-Action Preparations; Drug Design; Epilepsy, Gener | 2009 |
Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Antipsychotic Agents; Carbamazepine; Child; Clinic | 2004 |
Efficacy and tolerability of the new antiepileptic drugs, II: Treatment of refractory epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society.
Topics: Acetates; Adolescent; Adult; Age Factors; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Tr | 2004 |
Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epile
Topics: Acetates; Adult; Amines; Anticonvulsants; Carbamazepine; Child; Clinical Trials as Topic; Cyclohexan | 2004 |
2 trials available for zonisamide and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Open-label, long-term safety study of zonisamide administered to children and adolescents with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Adminis | 2009 |
Zonisamide decreases cortical excitability in patients with idiopathic generalized epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Electric Stimulation; Epilepsy, Generalized; Evoked Potentials, | 2008 |
12 other studies available for zonisamide and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Risk factors of paradoxical reactions to anti-seizure medication in genetic generalized epilepsy.
Topics: Adult; Anticonvulsants; Epilepsy, Generalized; Humans; Lamotrigine; Levetiracetam; Myoclonic Epileps | 2021 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes.
Topics: Adult; Ambulances; Anticonvulsants; Case-Control Studies; Cost Savings; Drug Costs; Drugs, Generic; | 2009 |
Efficacy and tolerability of zonisamide in idiopathic generalized epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Electroencephalography; | 2009 |
The usefulness of olfactory bulb kindling as a model for evaluation of antiepileptics.
Topics: Amygdala; Animals; Anticonvulsants; Behavior, Animal; Carbamazepine; Disease Models, Animal; Electri | 2010 |
Our clinical experience with zonisamide in resistant generalized epilepsy syndromes.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Confusion; Disorders of Excessive Somno | 2011 |
Efficacy and tolerability of zonisamide in juvenile myoclonic epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Dose-Response Relationship, Drug; Drug Interactions; Drug | 2004 |
[Effective and 15 years experience. New add-on option in epilepsy therapy]].
Topics: Anticonvulsants; Body Weight; Child; Controlled Clinical Trials as Topic; Dose-Response Relationship | 2005 |
Efficacy of levetiracetam at 12 months in children classified by seizure type, cognitive status, and previous anticonvulsant drug use.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Broad-spectrum efficacy of zonisamide at 12 months in children with intractable epilepsy.
Topics: Adolescent; Adult; Anticonvulsants; Child; Child, Preschool; Cognition; Dose-Response Relationship, | 2005 |
Efficacy and safety of zonisamide monotherapy in a cohort of children with epilepsy.
Topics: Adolescent; Anticonvulsants; Child; Cohort Studies; Epilepsies, Partial; Epilepsy, Generalized; Fema | 2006 |
Smoldering myeloma associated with zonisamide treatment.
Topics: Adult; Agammaglobulinemia; Anticonvulsants; Epilepsy, Generalized; Humans; Immunoglobulin lambda-Cha | 2002 |
Methodological requirements for clinical trials in refractory epilepsies--our experience with zonisamide.
Topics: Adolescent; Anticonvulsants; Child; Child, Preschool; Clinical Trials as Topic; Epilepsies, Partial; | 1992 |